Merck & Co. Terns Pharma Deal – Merck & Co. announced that it has agreed to acquire California-based biotech firm Terns Pharmaceuticals in a definitive all-cash transaction valued at approximately $6.7 billion. The board of directors of both companies has approved the deal, which is expected to close in the second quarter of 2026, subject to regulatory clearance and customary closing conditions.
Deal Terms and Strategic Focus
Under the terms of the agreement, Merck will pay $53.00 per share in cash to Terns shareholders, representing a significant premium to recent trading prices. The purchase price reflects the combined equity value of about $6.7 billion, enhancing Merck’s oncology portfolio through the addition of promising hematology assets.
Merck’s acquisition of Terns is aimed at bolstering its cancer drug pipeline, especially in the area of hematologic malignancies. TERN-701, the lead candidate, TERN-701, is an investigational oral allosteric BCR-ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for chronic myeloid leukemia (CML). The drug is designed to bind a distinct site on the target protein, which could offer advantages over existing therapies and address unmet needs in patients with treatment resistance or intolerance.
Market and Clinical Implications
Industry reports state that Merck’s agreement to acquire Terns Pharmaceuticals is designed to expand its oncology pipeline, with a particular focus on the company’s lead candidate TERN-701. The investigational therapy, an oral allosteric BCR::ABL1 inhibitor, is currently in Phase 1/2 development for certain patients with chronic myeloid leukemia. Early clinical data released by Terns has drawn attention for its potential to offer an alternative option in CML treatment.
The acquisition remains subject to regulatory review and the completion of a tender offer for Terns’ outstanding shares. Following the close of the transaction, Merck will assume responsibility for continuing the clinical development of TERN-701 as part of its broader oncology strategy.
The deal reflects Merck’s ongoing effort to strengthen its position in cancer therapeutics and add new assets to its pipeline. The company has stated that the transaction will support its long-term focus on advancing medicines in areas of significant need, including hematologic malignancies.
